Form 4: Labcorp EVP reports award vesting and 10b5-1 sale

Labcorp EVP Jonathan C. Meltzer received 2,388 performance shares, withheld 711 shares for taxes, and sold 839 shares under a Rule 10b5-1 plan, ending with 3,620.3256 shares owned.

Summary

• Reporting person: Jonathan C. Meltzer, EVP, Operations of Labcorp Holdings Inc. (LH).
• Acquired 2,388 common shares at $0 on 03/26/2026 from a performance award granted on 02/07/2023 tied to the three-year period ended 12/31/2025.
• Withheld 711 shares on 03/26/2026 to satisfy tax obligations at a price of $268.38 per share.
• Sold 839 shares on 03/27/2026 at $267.05 per share pursuant to a Rule 10b5-1 trading plan.
• Beneficial ownership after all reported transactions: 3,620.3256 common shares (direct).
• The Rule 10b5-1 checkbox was marked, and the form was signed on 03/30/2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine insider vesting and planned sale with neutral implications; award vesting is a mild positive, while the small sale and tax withholding are standard and not thesis-changing.

Positives

• Performance award vested, resulting in 2,388 shares acquired for $0 on 03/26/2026, indicating completion of the 2023–2025 performance cycle.
• Sale conducted under a Rule 10b5-1 plan, which helps reduce concerns about timing or discretion.
• Post-transaction ownership remains at 3,620.3256 shares, maintaining ongoing executive equity alignment.

Negatives

• Insider sale of 839 shares at $267.05 on 03/27/2026 may be perceived as a reduction in exposure.
• 711 shares were withheld for taxes at $268.38 on 03/26/2026, reducing the net shares retained.
• Beneficial ownership decreased from 5,170.3256 shares immediately after vesting to 3,620.3256 shares after tax withholding and sale (a reduction of 1,550.0 shares).

Future Outlook

No forward-looking statements or guidance provided.

Management Comments

• Shares were acquired on 03/26/2026 pursuant to a performance award granted on 02/07/2023 for the three-year period ended 12/31/2025.
• A portion of shares (711) was withheld to satisfy tax withholding obligations.
• The 03/27/2026 sale (839 shares) was executed under a Rule 10b5-1 trading plan.

Industry Context

StockSavvy.ai notes that executive equity vesting with concurrent tax withholding and planned sales under Rule 10b5-1 is common across healthcare services, aligning with typical practices seen at peers such as Quest Diagnostics; such transactions rarely alter fundamentals or industry positioning.

Comparison to Industry Standards

• Use of Rule 10b5-1 trading plans is standard among large-cap healthcare services firms (e.g., Quest Diagnostics executives) to systematize sales and reduce timing concerns.
• Tax withholding of shares at vesting mirrors common compensation practices across S&P 500 constituents to meet immediate tax obligations.
• The absolute size of the sale (839 shares) is modest relative to market float, consistent with routine post-vesting liquidity moves by executives at comparable companies.

Stakeholder Impact

• Executive beneficial ownership now totals 3,620.3256 shares, providing ongoing alignment with shareholders.
• The planned sale under Rule 10b5-1 may reassure investors regarding trading discipline and governance.
• Operational and financial impact is negligible given the small number of shares relative to the company’s outstanding float.

Key Dates

Keywords

Labcorp, LH, Form 4, insider transaction, Rule 10b5-1, performance award, executive compensation, share sale, stock withholding, Jonathan C. Meltzer, EVP Operations